Share this

Risk Factors for ESBL &MDR P.aeruginosa

Reference:

  1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008 Mar;8(3):159-66. doi: 10.1016/S1473-3099(08)70041-0. PMID:18291338.

Reference:

  1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006 Jan;50(1):43-8. doi: 10.1128/AAC.50.1.43-48.2006. PMID: 16377665; PMCID: PMC1346794.
  2. Davies J. C. (2002). Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatric respiratory reviews, 3(2), 128–134. https://doi.org/10.1016/s1526-0550(02)00003-3
  3. Manfredi R, Nanetti A, Ferri M, Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol. 2000 Feb;16(2):111-8. doi: 10.1023/a:1007626410724. PMID: 10845259.
  4. Meynard JL, Barbut F, Guiguet M, Batisse D, Lalande V, Lesage D, Guiard-Schmid JB, Petit JC, Frottier J, Meyohas MC. Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect. 1999 May;38(3):176-81. doi: 10.1016/s0163-4453(99)90247-5. PMID: 10424798.
  5. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia. Clin Microbiol Infect. 2005 May;11(5):415-8. doi:10.1111/j.1469-0691.2005.01102.x. PMID: 15819873.

AE-NON-00509 | Exp 30 Sept 2026